MapLight Therapeutics Inc (MPLT)

MapLight Therapeutics Inc. is a clinical-stage biopharmaceutical company focused on developing treatments for debilitating central nervous system disorders. Its pipeline includes ML-007C-MA, a fixed-dose combination of an M1/M4 muscarinic agonist being studied for schizophrenia and Alzheimer’s disease psychosis; ML-004 for social communication deficits and irritability associated with autism spectrum disorder; ML-021 for motor deficits in Parkinson’s disease; ML-055 for neuropsychiatric conditions; and ML-009, a G-protein-coupled receptor 52 positive allosteric modulator for disorders involving hyperactivity, impulsivity, and agitation. The company also works on a platform designed to identify neural circuits linked to disease and to target those circuits for therapeutic modulation. Formerly known as Alvarado Therapeutics, Inc., the company adopted the MapLight Therapeutics name in August 2019 and was incorporated in 2018. It is based in Redwood City, California.

Jump between the core stock analysis sections, valuation data, fair value models, technical outlook, and FAQ.